Loading
A phase 2 trial of Capecitabine, Fluorouracil, Atezolizumab in colorectal cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT05009069 by Hoffmann-La Roche, with 58 participants enrolled, started 2022-03-18 and due to reach its primary completion in 2023-11-21. Interventions recorded: Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab. Conditions listed: Rectal Neoplasms, Rectal Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TIGIT blockade, Tiragolumab, Atezolizumab, Immune checkpoint inhibitors.
Shares TIGIT blockade, Tiragolumab, Atezolizumab, Roche / Genentech.
Shares Tiragolumab, Atezolizumab, Immune checkpoint inhibitors.
Shares TIGIT blockade, Tiragolumab, Atezolizumab, Immune checkpoint inhibitors.
Shares Tiragolumab, Atezolizumab, Roche / Genentech.
Shares Atezolizumab, Roche / Genentech, Immune checkpoint inhibitors.
Shares Atezolizumab, Fluorouracil (5-FU), Rectal cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/